Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
April 10, 2026
Biotechnology
-
-
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer’s Disease 6-Month NDA Submission
April 10, 2026
-
BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications
April 10, 2026
-
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
April 9, 2026
-
Onconetix Highlights Realbotix’s Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
April 9, 2026
-
Biofrontera Inc.: A Dermatology Company Scaling with Momentum
April 8, 2026
-
Quantum-Si Announces First Customer Samples Tested on the Proteus(TM) Prototype System
April 8, 2026
-
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities
April 8, 2026
-
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
April 8, 2026
-
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies,
April 8, 2026
-
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company’s Runway into Late 2027/Early 2028
April 7, 2026
-
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
April 7, 2026
-
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
April 6, 2026
-
Quantum-Si Announces the Start of the Proteus(TM) Roadshow
April 6, 2026
-
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
April 3, 2026
-
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
April 3, 2026